A Precision Nanomedicine Platform For Pulmonary And Organ Fibrosis
SUMMARY
A targeted nanomedicine platform for delivering therapeutics to activated fibroblasts in pulmonary fibrosis and other fibrotic diseases
The Unmet Need: Current pulmonary fibrosis therapies slow decline for some patients but do not adequately stop progression, leaving a major need for more effective and better tolerated treatments
- Pulmonary fibrosis is a serious and progressive condition characterized by excessive scar formation in the lungs, which gradually impairs breathing and gas exchange. Current treatment options remain limited, and many patients continue to experience disease progression despite available therapy. The disease burden is significant because it is associated with declining lung function, poor quality of life, and high mortality. A central feature of fibrotic disease is the abnormal activation of fibroblasts, which contributes to the buildup of scar tissue and loss of normal organ structure.
The Proposed Solution: A fibroblast-targeted nanoparticle platform designed to selectively deliver anti-fibrotic therapeutics to activated fibroblasts and thereby suppress fibrosis at its cellular source
- The faculty inventor developed a targeted nanomedicine platform designed to deliver therapeutic agents directly to activated fibroblasts, which are key drivers of scar formation in fibrotic disease. Its core innovation is not just the therapeutic payload, but the ability to concentrate treatment in the cell population most responsible for disease progression. By focusing delivery on activated fibroblasts, the approach aims to improve therapeutic precision relative to broadly distributed systemic treatments. This may create a better balance between efficacy and tolerability, which is especially important in chronic fibrotic diseases where long-term treatment is often required. The platform may support multiple payloads and could have relevance in other fibroblast-driven diseases such as cardiac and kidney fibrosis.
ADVANTAGES
-
Cell-targeted delivery
-
Mechanism-based anti-fibrotic intervention
-
Potential compatibility with multiple payload classes
-
Platform extension beyond a single organ system
APPLICATIONS
-
Idiopathic pulmonary fibrosis
-
Progressive pulmonary fibrosis / fibrosing ILD
-
Kidney fibrosis
-
Cardiac fibrosis